Mirabegron Eg

Mirabegron, the active ingredient in Mirabegron Eg, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the management of overactive bladder, reducing urinary urgency, frequency and urge urinary incontinence in adult patients by relaxing the detrusor muscle and increasing functional bladder capacity.

GNH USA supplies Mirabegron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is used to treat conditions related to overactive bladder and urinary storage dysfunction.

- Overactive bladder: reduces urgency, frequency and urge incontinence. - Urinary urgency: provides relief by increasing bladder capacity. - Urinary frequency: decreases daytime voiding episodes. - Urge urinary incontinence: helps control involuntary leakage.

Common Side Effects: - Hypertension: elevated blood pressure may occur. - Nasopharyngitis: mild upper respiratory tract infection. - Headache: occasional throbbing or tension headache. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary tract infection: symptoms of infection may appear.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate. - Severe hypertension: markedly high blood pressure. - Angioedema: swelling of face, lips or throat. - Myocardial infarction: rare heart attack events. - Anaphylaxis: severe allergic reaction.

Before initiating therapy, consider the following precautions. - Assess blood pressure: monitor for hypertension before and during treatment. - Review renal function: adjust use in patients with severe impairment. - Evaluate cardiovascular status: use cautiously in arrhythmias or heart disease. - Avoid in uncontrolled hypertension: contraindicated in markedly elevated pressure. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with several drug classes; monitor accordingly.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine): may increase mirabegron exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Antihypertensive agents: may attenuate blood‑pressure‑lowering effect. - Nitrates: additive vasodilatory effect may cause hypotension. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - Anticholinergic agents: may increase risk of urinary retention.